Axsome Therapeutics reports strong Q4 2024 revenues, driven by increased sales of Auvelity and Sunosi. Anticipated milestones and FDA approval for Symbravo make AXSM a top pick for 2025.

Total 4Q and full year 2024 net product revenue of $118.8 million and $385.7 million, respectively, representing 66% and 88% year-over-year ...

Reports Q4 revenue $118.8M, consensus $117.84M. “2024 was another defining year for Axsome, driven by strong commercial growth and a rapidly ...

Drugs that can prevent or relieve migraine attacks are only effective for some people. Research is starting to untangle the ...

If you're dealing with recurring headaches that come with the symptoms mentioned and mess up your daily routine, it's time to ...

Bleeding gums may not seem like a serious issue. But if it becomes chronic, you might be surprised to hear that it can be a clear warning your heart isn’t working as it should. While pressure or ...

After adjusting for potential confounders (age, sex, race, use of birth control, pregnancy), findings showed propranolol use was associated with a significant reduction in the risk of stroke among ...

Propranolol is associated with a reduced risk for overall stroke among women with migraine, with a more pronounced protective effect for ischemic stroke.

Axsome settles Auvelity patent litigation with Teva, delaying a generic launch until 2038. Analysts see growth potential with Symbravo's migraine approval.

A common blood pressure medication used to prevent migraines may also significantly reduce the risk of ischemic stroke in women, according to a new study. The research, presented at the American ...

Ubrelvy (ubrogepant) and Nurtec (rimegepant) are prescription medications approved to help manage and offer relief for people dealing with migraine headaches with or without aura. Both belong to a ...